“…High bone mass in patients with sclerostin deficiency is present throughout the skeleton, including non-weight-bearing regions, such as the face and skull (40), indicating that anti-sclerostin antibodies are not agents that decrease the mechanical strain threshold for bone modeling; treatment with an anti-sclerostin antibody is highly efficacious even under conditions with impaired physical activity (50–54), whereas enhancing skeletal response to physical activity cannot effectively improve bone fragility caused by reduced skeletal loading. Accordingly, treatment with an anti-sclerostin antibody is likely to strengthen the skeleton, without any specific direction in contrast to exercise, to prevent fall-related fractures such as in the hip (55). …”